Additional file 8 of Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody

Kaneko, Yutaro; Hatano, Ryo; Hirota, Naoto; Isambert, Nicolas; Trillet-Lenoir, Véronique; You, Benoit; Alexandre, Jérôme; Zalcman, Gérard; Valleix, Fanny; Podoll, Thomas; Umezawa, Yoshimi; Takao, Seiichi; Iwata, Satoshi; Hosono, Osamu; Taguchi, Tetsuo; Yamada, Taketo; Dang, Nam H.; Ohnuma, Kei; Angevin, Eric; Morimoto, Chikao

doi:10.6084/m9.figshare.14302959.v1

40364_2021_273_MOESM8_ESM.pptx (59.39 kB)

Additional file 8 of Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody

presentation

posted on 2021-03-25, 08:40 authored by Yutaro Kaneko, Ryo Hatano, Naoto Hirota, Nicolas Isambert, Véronique Trillet-Lenoir, Benoit You, Jérôme Alexandre, Gérard Zalcman, Fanny Valleix, Thomas Podoll, Yoshimi Umezawa, Seiichi Takao, Satoshi Iwata, Osamu Hosono, Tetsuo Taguchi, Taketo Yamada, Nam H. Dang, Kei Ohnuma, Eric Angevin, Chikao Morimoto

Additional file 8: Table S7. Correlation between serum sCD26/DPP4 titer variation (%) and tumor volume change (%) or PFS (days) in 9 MM, male cases with Q2W administration by PPMC or SRDC analysis.